Physician profile
Sharette Gray
NPI 1346300696
$1,558.60
in general payments reported to CMS, 2019-2025
15 companies · $13.78 in 2025
The $13.78 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.59 · 2020: $596 · 2021: $400 · 2022: $448 · 2024: $53.35 · 2025: $13.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $67.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $67.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $435.69 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $168.67 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $159.21 | 2020-2022 | |
| Allergan, INC. | $141.84 | 2020 | |
| Lundbeck LLC | $141.49 | 2020-2022 | |
| Alkermes, INC. | $117.96 | 2021-2022 | |
| Neos Therapeutics, Lp | $101.85 | 2020-2022 | |
| Tris Pharma INC | $89.75 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $67.13 | 2024-2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.06 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $30.13 | 2019-2020 | |
| Eisai INC. | $17.73 | 2020 | |
| Owp Pharmaceuticals, INC. | $16.54 | 2020 | |
| Shire North American Group INC | $14.61 | 2019 | |
| Adlon Therapeutics L.P. | $12.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharette Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.